Preference-Cliff Defense: A 12-Month Plan for Bangladesh's November 2026 LDC Graduation

Diagnosis

Bangladesh exits Least Developed Country status in November 2026. Graduation is an achievement, but it removes three specific trade preferences at once, and the curated assessment names all three: EU Everything But Arms (EBA), India's Duty Free Tariff Preference (DFTP) scheme, and the pharmaceutical TRIPS waiver.

Each loss bites a different part of the economy. EBA gives Bangladeshi garments duty-free entry to the European Union; losing it pushes those exports into the EU's standard tariff schedule unless a successor arrangement is secured first. India's DFTP delivers similar margin protection on the regional market. The pharma TRIPS waiver lets Bangladeshi firms produce patented medicines without paying for the patent, the legal foundation of the country's generic drug industry; graduation closes that exemption.

The reason this matters now is timing. These are not gradual erosions. They switch off on a fixed date, and the instruments that replace them, an EU GSP+ application, a bilateral understanding with India, and a domestic patent and procurement framework for pharma, all require months of preparatory work, negotiation, and counterpart approval that cannot begin after the cliff. The Ministry of Commerce (MoC) is the lead responsible body and owns the window that is closing.

Recommended actions

1. Lock the EU successor track. Owner: MoC, working through the EU's GSP framework. Mechanism: file and complete the GSP+ eligibility and ratification dossier, with Bangladesh Standards and Testing Institution (BSTI) certifying the product-standard and conformity-assessment compliance the EU conditions require. Observable signal: the EU formally acknowledges Bangladesh's GSP+ application and opens the review, rather than leaving exports to default to standard tariffs at graduation.
2. Secure continued access to the Indian market. Owner: MoC, supported by the Bangladesh Trade and Tariff Commission (BTTC) for tariff-line analysis. Mechanism: a bilateral trade arrangement or preferential understanding with India that carries forward DFTP-equivalent treatment on the lines that matter most to exporters. Observable signal: a signed or initialled bilateral text, or a standstill commitment from India covering the graduation date.
3. Build the post-waiver pharma framework. Owner: MoC coordinating with the relevant drug-regulatory and intellectual-property authorities. Mechanism: a domestic patent, licensing, and public-procurement regime (compulsory-licensing provisions, a transition schedule for affected molecules, and a government procurement carve-out for essential medicines) that keeps generic supply legal and affordable after the TRIPS waiver ends. Observable signal: published transition rules and licensing terms that manufacturers can plan production around.
4. Cut the non-tariff cost of trading. Owner: Chittagong Port Authority (CPA) for port throughput and BSTI for conformity infrastructure, coordinated by MoC. Mechanism: faster cargo clearance, accredited testing labs, and recognised certification so that tariff savings are not eaten by border friction. Observable signal: measurable falls in dwell time and a rising share of exporter shipments cleared on accredited certificates.
5. Stand up an investment-and-diversification response. Owner: Bangladesh Investment Development Authority (BIDA), coordinated by MoC. Mechanism: a targeted facilitation track for export sectors beyond ready-made garments, tied to the new market-access terms. Observable signal: new investment registrations and approvals in non-garment export lines.

Sequencing (first 12 months)

Start with the EU and India tracks (actions 1 and 2): they have the longest counterpart lead times and the largest export exposure, and they cannot be improvised after November 2026. Filing the GSP+ dossier early unlocks the EU review clock; opening the India channel early unlocks a standstill that prevents a hard tariff snap-back. In parallel, BSTI compliance work (inside action 1) and the pharma framework (action 3) proceed, because both are domestic deliverables MoC controls without waiting on a foreign counterpart. Port and investment work (actions 4 and 5) run continuously and compound the value of whatever market access is secured.

Risks and constraints

The binding constraint is that two of the three tracks depend on foreign counterparts, the EU and India, whose timelines MoC cannot dictate. GSP+ carries conditionality (standards, conventions, monitoring) that requires real domestic reform, not a signature. The pharma transition is politically sensitive: protecting generic supply while honouring new patent obligations sets affordability against legal exposure. Fiscally, BSTI accreditation, lab capacity, and port upgrades all compete for budget against other priorities, and under-investment here quietly erases any tariff gain at the border.

Bottom line

Graduation removes EBA, DFTP, and the pharma TRIPS waiver on a fixed November 2026 date, so the successor instruments must be in motion before then, not after. The Ministry of Commerce should front-load the EU GSP+ filing and the India arrangement now, because those are the slowest to close and the most costly to miss.